A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading to large untargeted regions that escape therapy. We present a modeling framework which includes the systemic distribution, vascular permeability, interstitial transport, as well as binding and payload release kinetics of ADC-therapeutic agents in mouse xenografts. We focused, in particular, on receptor dynamics such as endocytic trafficking mechanisms within cancer cells, to simulate their impact on tumor mass shrinkage upon ADC administration. Our model identified undesirable tumor properties that can impair ADC tissue homogeneity, further compromising ADC success, and explored ADC design optimization scenarios to counteract upon such unfavorable intrinsic tumor tissue attributes. We further demonstrated the profound impact of cytotoxic payload release mechanisms and the role of bystander killing effects on tumor shrinkage. This model platform affords a customizable simulation environment which can aid with experimental data interpretation and the design of ADC therapeutic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the histological architecture of mCRPC—characterized by dense stroma, low vascularity, and high between-tumor heterogeneity—has limited ADC penetration and distribution within tumor tissue219–222.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [221]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Isolation by Size of Epithelial Tumor Cells
Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schütze, K., Capron, F., Franco, D., Pazzagli, M., Vekemans, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64706-2 · Cited by 1,069
Receptors; models for binding, trafficking and signaling
(1997) · General Pharmacology: The Vascular System · doi:10.1016/s0306-3623(97)90087-2 · Cited by 855
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Research works printed but not linked: 1
- M Dellian, 2000, Vascular permeability in a human tumour xenograft: molecular charge dependence, British Journal of Cancer, 82, 1513
Cited by
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 277
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Computational oncology — mathematical modelling of drug regimens for precision medicine
Barbolosi, D., Ciccolini, J., Lacarelle, B., Barlési, F., & André, N. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.204 · Cited by 221
Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128
Cilliers, C., Guo, H., Liao, J., Christodolu, N., & Thurber, G. M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9940-z · Cited by 125
Kopp, A., Hofsess, S., Cardillo, T. M., Govindan, S. V., Donnell, J., & Thurber, G. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0375 · Cited by 103
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain, M., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 91
Xenaki, K. T., Dorresteijn, B., Muns, J. A., Adamzek, K., Doulkeridou, S., Houthoff, H., Oliveira, S., & Henegouwen, P. M. P. V. B. E. (2021) · Theranostics · doi:10.7150/thno.57510 · Cited by 92
Tsumura, R., Manabe, S., Takashima, H., Koga, Y., Yasunaga, M., & Matsumura, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.016 · Cited by 85
Helmlinger, G., Sokolov, V., Peskov, K., Hallow, K. M., Kosinsky, Y., Voronova, V., Chu, L., Yakovleva, T., Azarov, I., Kaschek, D., et al. (2019) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12426 · Cited by 72
Self-citationKhera, E., & Thurber, G. M. (2018) · BioDrugs · doi:10.1007/s40259-018-0302-5 · Cited by 80
Wu, Y., Li, Q., Kong, Y., Wang, Z., Lei, C., Li, J., Ding, L., Wang, C., Cheng, Y., Wei, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.013 · Cited by 75
Khera, E., Cilliers, C., Bhatnagar, S., & Thurber, G. M. (2017) · Molecular Systems Design & Engineering · doi:10.1039/c7me00093f · Cited by 70
DNA damaging agent-based antibody-drug conjugates for cancer therapy
Fu, Y., & Ho, M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby007 · Cited by 72
89Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development
McKnight, B. N., & Viola, N. T. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3605 · Cited by 61
What makes a good antibody–drug conjugate?
Cecco, M. D., Galbraith, D. N., & McDermott, L. L. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1880562 · Cited by 62
Brandl, F., Busslinger, S. D., Zangemeister‐Wittke, U., & Plückthun, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.004 · Cited by 58
Cheng, Y., Thalhauser, C. J., Smithline, S., Pagidala, J., Miladinov, M., Vezina, H. E., Gupta, M., Leil, T. A., & Schmidt, B. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0100-x · Cited by 54
Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
Vezina, H. E., Cotreau, M. M., Han, T. H., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.981 · Cited by 52
Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
Malik, P. R. V., Phipps, C. J., Edginton, A. N., & Blay, J. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2259-3 · Cited by 51
Burton, J. K., Bottino, D. C., & Secomb, T. W. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0390-2 · Cited by 48
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point
Tolcher, A. W. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281103 · Cited by 49
Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates
Li, W., Veale, K. H., Qiu, Q., Sinkevicius, K. W., Maloney, E. K., Costoplus, J. A., Lau, J., Evans, H. L., Setiady, Y. Y., Ab, O., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00301 · Cited by 51
The molecular design of and challenges relating to sensitizers for cancer sonodynamic therapy
Zhou, Y., Wang, M., & Dai, Z. (2020) · Materials Chemistry Frontiers · doi:10.1039/d0qm00232a · Cited by 46
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Pérez, V. M. M., Baselga, M., & Schuhmacher, A. J. (2024) · Cancers · doi:10.3390/cancers16152681 · Cited by 45
Scheuher, B., Ghusinga, K. R., McGirr, K., Nowak, M., Panday, S., Apgar, J. F., Subramanian, K., & Betts, A. M. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09884-6 · Cited by 43
Widdison, W. C., Ponte, J. F., Coccia, J. A., Lanieri, L., Setiady, Y. Y., Dong, L., Skaletskaya, A., Hong, E., Wu, R., Qiu, Q., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00430 · Cited by 40
Durbin, K. R., Phipps, C. J., & Liao, X. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0672 · Cited by 40
Menezes, B., Cilliers, C., Wessler, T., Thurber, G. M., & Linderman, J. J. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0391-1 · Cited by 36
Haraya, K., Tsutsui, H., Komori, Y., & Tachibana, T. (2022) · Pharmaceuticals · doi:10.3390/ph15050508 · Cited by 35
Prospects and progress of antibody-drug conjugates in solid tumor therapies
Govindan, S. V., Sharkey, R. M., & Goldenberg, D. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1173203 · Cited by 33
Weddell, J. C., Chiney, M. S., Bhatnagar, S., Gibbs, J. P., & Shebley, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12892 · Cited by 33
Kenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
Petrenko, V. A., & Gillespie, J. W. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1218463 · Cited by 32
Wayua, C., Roy, J., Putt, K. S., & Low, P. S. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00218 · Cited by 31
Mechanisms of resistance to antibody-drug conjugates in breast cancer
Çerçi, B., Saatci, Ö., Basik, M., & Şahin, Ö. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101353 · Cited by 26
Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates
Zuo, P. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00475-8 · Cited by 26
Menezes, B., Linderman, J. J., & Thurber, G. M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000503 · Cited by 24
Nessler, I., Rubahamya, B., Kopp, A., Hofsess, S. J., Cardillo, T. M., Sathyanarayan, N., Donnell, J., Govindan, S. V., & Thurber, G. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0437 · Cited by 23
Glatt, D. M., Beckford-Vera, D., Parrott, M. C., Luft, J. C., Benhabbour, S. R., & Mumper, R. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00063 · Cited by 23
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Abazari, M. A., Soltani, M., & Kashkooli, F. M. (2023) · Physics of Fluids · doi:10.1063/5.0130259 · Cited by 21
Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?
Jiang, X., Sun, L., Hu, C., Zheng, F., Lyu, Z., & Shao, J. (2023) · Marine Drugs · doi:10.3390/md21090496 · Cited by 20
Development of and insights from systems pharmacology models of antibody‐drug conjugates
Lam, I., Reddy, V. P., Ball, K., Arends, R. H., & Gabhann, F. M. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12833 · Cited by 19
Sunoqrot, S., Hamed, R., Abdel‐Halim, H., & Tarawneh, O. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666161222111656 · Cited by 20
Byun, J. H., Han, D., Cho, H., Yoon, I., & Jung, I. H. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01209-2 · Cited by 19
Kulesza, A. J., Couty, C., Lemarre, P., Thalhauser, C. J., & Cao, Y. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09930-x · Cited by 19
Modeling to capture bystander-killing effect by released payload in target positive tumor cells
Byun, J. H., & Jung, I. H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5336-7 · Cited by 16
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
Liao, M. Z., Leipold, D. D., Chen, S., Li, Z., Kamath, A. V., & Li, C. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2351044 · Cited by 15
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
Lauro, V. D., Rizzo, A., Tafuro, M., Fina, E., Martinelli, C., Calderaio, C., Rienzo, R. D., Pirolo, M., Fanizzi, A., Massafra, R., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103023 · Cited by 17
Lin, J. H., Guo, Y., & Wang, W. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0122-9 · Cited by 15
AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies
Stein, A., & Ramakrishna, R. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12169 · Cited by 14
Byun, J. H., & Jung, I. H. (2019) · Applied Mathematical Modelling · doi:10.1016/j.apm.2019.10.037 · Cited by 14
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)
Beaumont, K. C., Pike, A., Davies, M., Savoca, A., Vasalou, C., Harlfinger, S., Ramsden, D., Ferguson, D., Hariparsad, N., Jones, O., et al. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2141667 · Cited by 13
Self-citationHER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
Liang, Y., Lei, R., Tan, J., Fang, J., Yu, L. C., Tan, S., Nie, Y., Jiang, Q., Xiao, X., & Saw, P. E. (2023) · BIO Integration · doi:10.15212/bioi-2023-0006 · Cited by 13
Liu, J., Yan, F., Chen, H., Wang, W., Liu, W., Hao, K., Wang, G., Zhou, F., & Zhang, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13909 · Cited by 13
Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery
Huynh, V. A., Jesmer, A. H., Shoaib, M. M., D'Angelo, A. D., Rullo, A. F., & Wylie, R. G. (2018) · ChemBioChem · doi:10.1002/cbic.201800579 · Cited by 14
Menezes, B., Khera, E., Calopiz, M. C., Smith, M. D., Ganno, M. L., Cilliers, C., Abu‐Yousif, A. O., Linderman, J. J., & Thurber, G. M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00756-4 · Cited by 12
Typical Antibody–Drug Conjugates
Lambert, J. M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch1 · Cited by 14
Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies
de Almeida, V. M., Soares, M. B. P., & Santos‐Filho, O. A. (2025) · Pharmaceuticals · doi:10.3390/ph18081198 · Cited by 12
Curry, S. D., Bower, B. M., Saemundsson, S. A., Goodwin, A. P., & Cha, J. N. (2025) · Nanoscale Advances · doi:10.1039/d4na00823e · Cited by 8
Huet, S., Labouebe, M. Z., Castro, R., Jacquot, P., Pedrault, J., Viollet, S., Simaeys, G. V., Doumont, G., Larbanoix, L., Zindy, E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0805 · Cited by 7
Topoisomerase Inhibitors as Antibody–Drug Conjugate (ADC) Payloads
Govindan, S. V., Cardillo, T. M., & Goldenberg, D. M. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00166 · Cited by 7
Passive Membrane Permeability of Sizable Acyclic β-Hairpin Peptides
Moxam, J., Naylon, S. H., Richaud, A. D., Zhao, G., Padilla, A., & Roche, S. P. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00486 · Cited by 6
Stamati, I., Yahioglu, G., Diez-Posada, S., Pomowski, A., Perez-Castro, I., Stewart, A., Bouché, L., Constantinou, A., Stenton, B. J., Saouros, S., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1182 · Cited by 5
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer
Fang, J., Alhaskawi, A., Dong, Y., Cheng, C., Xu, Z., Tian, J., Abdalbary, S. A., & Lü, H. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300614 · Cited by 6
Li, H., & Li, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-22 · Cited by 5
Lim, R. K. V., Buschman, M. D., Khasanov, A. B., Ledesma, A., Chen, J., Nguyen, T., Guo, X., Li, L., Huang, J., Niu, J., et al. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2292633 · Cited by 4
Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads
Lambert, J. M. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00031 · Cited by 4
Schmidt, B. J., Pan, C., Vezina, H. E., Sun, H., Leipold, D. D., & Gupta, M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch9 · Cited by 4
Stein, A. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/123240 · Cited by 4
Liu, Y., Wang, T., Chi, X., Yu, S., He, W., He, H., Wang, G., Hao, K., & Zhang, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125237 · Cited by 4
Bower, B. M., Curry, S. D., Goodwin, A. P., & Cha, J. N. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c01225 · Cited by 3
Wang, X. L., Hou, X., Tan, L., Chen, C., Chang, L., Han, B., Xing, Y. K., Zeng, Z., Zhou, Z., Lu, Q., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03215 · Cited by 3
Byun, J. H., Park, A., & Jung, I. H. (2020) · Journal of Applied Analysis & Computation · doi:10.11948/20190232 · Cited by 2
Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs
Ganz, D. E., Sexton‐Stallone, B., Kolewe, E. L., & Forbes, N. S. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.10.022 · Cited by 2
Ghosh, D., Sugimoto, H., Lee, J. Y., & Qian, M. G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00146 · Cited by 2
Next Generation of Antibody-Drug Conjugates for Breast Cancer
Srivastava, S., Osikoya, A., & Raman, D. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_424 · Cited by 1
Curry, S. D., Alina, T. B., Saemundsson, S. A., Rodríguez, M. C., Bower, B. M., Cha, J. N., & Goodwin, A. P. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c04443 · Cited by 1
Xu, W., Pan, C., He, Q., Zhu, X., & Xiang, X. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00443-4 · Cited by 1
Antibody-drug conjugate engineering: from design to efficacy and safety
Ocaña, A., Espinosa, J. R., Alonso‐Moreno, C., Győrffy, B., Tong, H., & Pandiella, A. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03057-w · Cited by 1
Antibody–Drug Conjugates: Clinical Strategies and Applications
Vezina, H. E., Lee, L., Schmidt, B. J., & Gupta, M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch12 · Cited by 1
Lam, I., Dai, D., Arends, R. H., Reddy, V. P., Ball, K., & Gabhann, F. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639376 · Cited by 1
Meid, A. D., Leiva-Escobar, I., Choi, S.-L., & Valente, D. (2026) · medRxiv · doi:10.64898/2026.01.30.26345218 · Cited by 1
An Introduction to Systems Biology and Quantitative Systems Pharmacology
Gomes, B. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12355-8
Self-citationUtilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer
McKnight, B. N. (2019) · Human Biology
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Children
Malik, P. R. V. (2021) · UWSpace (University of Waterloo)
Application of Nano-Delivery System in Tumor Immunotherapy
袁, 豪. (2023) · Hans Journal of Nanotechnology · doi:10.12677/nat.2023.134010
Exploring immunotherapy with antibody-drug conjugates in solid tumor oncology
Malemnganba, T., Pandey, A. K., Mishra, A., Mehrotra, S., & Prajapati, V. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.016
Pharmacokinetics of Therapeutic Antibodies and Derivatives
Chen, E. P. (2025) · Wiley eBooks · doi:10.1002/9781119650263.ch08
Mode of action for small molecules and GPCRs
Kenakin, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00026-1
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025
Yu, H., Dambra, R., Chan, G., Ishida, E., Khalilimeybodi, A., Krebs, N., Pilvankar, M., & Seeland, S. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2650189
Han, Y., Guo, Q., Cao, H., Qin, T., Zhang, X., Dong, Q., Huang, Y., Mao, Y., Wang, Z., Liu, Q., et al. (2026) · Medical Oncology · doi:10.1007/s12032-026-03317-3
Optimization of Affibody Affinity to Improve Distribution in Tumor Models
Bower, B. M., Ho, G. M., Saemundsson, S. A., Goodwin, A. P., & Cha, J. N. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c01111
Nikfar, M., Franzese, R. C., Struemper, H., Howell, B. A., & Melhem, M. R. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70352
Bending, D., Khera, E., Lam, I., Asiimwe, I. G., & Reddy, V. P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70768
Metadata
- Authors
- Vasalou, C., Helmlinger, G., & Gomes, B.
- Affiliations
- Novartis (United States) (US)
- Corresponding author
- Gomes, Bruce
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-18
- Volume
- 10
- Issue
- 3
- Pages
- e0118977
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4364906
- OpenAlex
- W2011733413
- Cited by
- 98
- References
- 49
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 8 · 2018: 9 · 2017: 14 · 2016: 7 · 2015: 3
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- antibody-drug conjugates, tumor penetration, tumor heterogeneity, vascular permeability, interstitial transport, endosomal trafficking, receptor dynamics, bystander killing, tumor shrinkage, xenograft models, pharmacokinetic modeling
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Kinetics, Models, Biological, Neoplasms, Drug Design, Immunoconjugates, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.